For diabetes, medications like Ozempic, Trulicity, Victoza, and Mounjaro are FDA-approved for glycemic control, while Wegovy, Saxenda, and Zepbound are specifically FDA-approved for chronic weight management
These peptides have the same basic sequence as the intended product but differ in charge due to chemical modifications
The Price & Trust Transparency Score looks at how clinics bridge that gap through fairness, safety, and follow-up
Women in midlife are most notably affected by hormonal shifts that are brought on by menopause, so altering or playing with any prescription for off-label use can be dangerous

Key factors influencing dose selection include: Treatment goals : Whether the primary aim is glycaemic control, weight reduction, or cardiovascular risk reduction Baseline HbA1c and blood glucose levels : Higher values may eventually require higher maintenance doses Body weight and BMI : Particularly relevant for weight management indications Renal function : Most GLP-1 medications (semaglutide, liraglutide, dulaglutide) do not require dose adjustment for kidney impairment, but exenatide and lixisenatide should be used with caution or avoided in severe renal impairment Concurrent medications : Especially other glucose-lowering agents that might increase hypoglycaemia risk Previous medication tolerance : History of gastrointestinal sensitivity influences titration speed Cardiovascular history : Some GLP-1 medications have proven cardiovascular benefits at specific doses Diabetic retinopathy status : Rapid improvement in blood glucose can temporarily worsen retinopathy, particularly with semaglutide [22] [23] Your doctor will typically schedule regular follow-up appointments during the initial months of treatment
